




HE 4 - ROMA

The novel potential marker for Ovarian Cancer

- Cancer Antigen (CA)125 has low sensitivity & specificity
- Human Epididymis Protein (HE4) is a better marker for detection of ovarian cancer, with increased sensitivity in early stage disease over that of CA 125
- HE4 in combination with CA 125 is a more accurate tool for diagnosis of ovarian cancer from a benign ovarian cyst or endometriosis

ROMA : Risk of Ovarian Malignancy Algorithm

- Stratification tool that combines CA125 and HE4 levels and uses an algorithm to compute malignancy risk in a patient with pelvic mass
- Correctly identifies 89% of epithelial ovarian cancers (EOC) and low malignant potential tumors as high risk and 75% of benign disease as low risk



	Sensitivity at 96% Specificity	
	HE 4	CA 125
Early stage vs Normal	86%	71%
Late stage vs Normal	80%	80%
All cases vs Benign	67%	40%

ROMA Report

Premenopausal	> or = 7.4%	: High risk of finding of EOC
	< 7.4%	: Low risk of finding EOC
Postmenopausal	> or = 25.3%	: High risk of finding of EOC
	< 25.3%	: Low risk of finding EOC

Prescribe HE4 Test* at Metropolis to Your Patients

* CA 125 & ROMA values are also included in the report

Ova-C